The 510(k) pathway sounds straightforward on paper: demonstrate substantial equivalence to a predicate, submit your documentation, get cleared. In practice, the biocompatibility section alone can generate multiple deficiency rounds if it's not built correctly from the start. That's where a medical device consulting firm comes in. Not as a rubber stamp, and not as someone who fills out forms. A firm with deep regulatory and toxicological expertise shapes the strategy behind yo

ISO 10993-6:2026 was published in April 2026, replacing the third edition from 2016. If you're running implantation studies or reviewing biocompatibility data packages right now, this is the version that applies. The changes aren't cosmetic. Several of them close gaps that have caused inconsistent study design and confusing regulatory submissions for years. This article covers what changed and what it means practically for manufacturers, CROs, and regulatory affairs teams. Wh

Every implantation study under ISO 10993-6:2026 is built on a comparison. Your test sample goes in alongside a control, and the tissue responses to both are evaluated side by side. The conclusion — whether your device produces an acceptable local tissue response — depends entirely on what that comparison shows. That makes control selection one of the most consequential decisions in implant study design. Get it wrong and borderline histopathology results become very difficult

One of the most expensive questions in implantable device development is also one of the most frequently answered too quickly: Do we need an implantation study? The reflex answer — "it's an implant, so yes" — has led to a lot of unnecessary animal studies and a lot of unnecessary cost. The correct answer depends on your specific device, your materials, your existing data, and how you've structured your overall biological evaluation under ISO 10993-1:2025. ISO 10993-6:2026, th

Choosing the wrong implant test site is one of the more avoidable mistakes in biocompatibility study design and one of the more consequential ones. If your test doesn't reflect how the device actually contacts tissue in clinical use, your data may not support the conclusions you need, and FDA reviewers will notice. Under ISO 10993-6:2026, the test sample must be implanted into or onto the tissues most relevant to the intended clinical use of the material. The choice of tissue

Medical device risk management is the systematic application of management policies, procedures, and practices to identify, evaluate, control, and monitor risks throughout the device lifecycle. Under the QMSR and ISO 14971:2019, risk management isn't a one-time premarket activity—it's an ongoing process integrated with design controls, biocompatibility evaluation, and quality system operations. For manufacturers navigating regulatory requirements in 2026, effective risk manag

Biocompatibility testing for medical devices has fundamentally changed under ISO 10993-1:2025. The familiar endpoint matrix that automatically prescribed which tests to conduct based on device contact type and duration no longer exists. Instead, manufacturers must conduct systematic biological risk assessment to determine when biocompatibility testing is necessary, which tests are appropriate, and how to justify those decisions scientifically. For medical device manufacturers

Biocompatibility is straightforward at its core: your device materials must not cause an unacceptable biological response in the body under their intended use conditions. In practice, that means you need to understand how your device contacts the body, for how long, what biological hazards exist, and how you'll demonstrate that biological risks are acceptable. What FDA Biocompatibility Requirements Actually Cover FDA uses biocompatibility evaluation to judge whether your devi

On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the FDA announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a groundbreaking initiative designed to accelerate Medicare beneficiary access to FDA-designated Breakthrough Devices. Combined with the expanding Total Product Life Cycle Advisory Program (TAP), these programs fundamentally change how manufacturers should approach development strategy, evidence gen

Contract research organizations occupy a unique position in the medical device ecosystem. While CROs don't typically hold FDA establishment registrations as manufacturers, the quality of services they provide directly impacts their clients' QMSR compliance, biocompatibility evaluations, and regulatory submissions. The QMSR's emphasis on process-based quality management, expanded FDA inspection authority, and integration of biocompatibility with design controls creates both ch

ISO 10993-1 sits at the center of how regulators expect you to think about biological safety. It is the international standard for biological evaluation of medical devices, and Part 1 provides the framework for structuring your entire biocompatibility strategy within a risk management process. The 2025 edition, represents the most significant change to biocompatibility evaluation in decades. The familiar endpoint matrix that guided testing decisions for over 30 years has been

The QMSR became effective February 2, 2026, replacing 21 CFR Part 820 as the foundation for medical device quality systems in the United States. While the two-year transition period allowed manufacturers to prepare, many organizations are still working to fully align their quality systems with QMSR requirements and ISO 13485:2016 expectations. Whether you're just beginning your transition or refining an implementation already underway, a systematic roadmap helps you priorit

Biocompatibility evaluation sits at the intersection of product safety, regulatory compliance, and quality system management. Under the QMSR , which incorporates ISO 13485:2016 by reference, biocompatibility must be fully integrated into your quality management system—not treated as a standalone testing exercise conducted outside your design and risk management processes. The publication of ISO 10993-1:2025 adds complexity and opportunity. The new standard's risk-based biol

The FDA medical device databases form an interconnected ecosystem that supports classification decisions, biocompatibility strategy, regulatory submissions, and ongoing compliance. If you understand what each database contains, you can move from guesswork to a traceable, defensible regulatory approach. Core FDA Device Databases Devices@FDA provides information on cleared and approved devices, including marketing pathway, product codes, and approval or clearance documentation

On February 2, 2026, FDA retired the Quality System Inspection Technique (QSIT) and implemented a new inspection process described in Compliance Program 7382.850 . This change represents more than updated procedures—it reflects a fundamental shift in how FDA assesses medical device quality management systems under the QMSR. For manufacturers and CROs, understanding the new inspection approach and preparing your quality system for FDA review is essential for maintaining compli

As of February 2, 2026, the FDA's Quality Management System Regulation (QMSR) has replaced 21 CFR Part 820 as the foundation for medical device quality systems in the United States. This transition incorporates ISO 13485:2016 by reference, harmonizing U.S. requirements with international quality management standards used by regulatory authorities worldwide. For medical device manufacturers, CROs, and regulatory affairs professionals, understanding what changed is essential fo

Bringing a medical device to the U.S. market means more than selecting a regulatory pathway. Your specific role shapes how you plan, generate, and defend biocompatibility and toxicological data within the FDA framework. Understanding Your Role in the Medical Device Approval Process Medical Device Manufacturers Manufacturers need a clear biocompatibility and toxicology strategy that starts at design input. Key challenges include: Translating intended use and contact duration

Medical device regulation in the United States sits squarely under the authority of the Food and Drug Administration, within the Center for Devices and Radiological Health (CDRH). If you plan to market a device in the U.S., you operate within this framework whether your product is a simple external accessory or an implantable system with long term patient contact. CDRH implements federal laws such as the Federal Food, Drug, and Cosmetic Act (FD&C Act) through binding regulat

Extractables and leachables analysis sits at the core of modern biocompatibility assessment for medical devices. If your device uses polymers, adhesives, colorants, tubing, coatings, or packaging, you are dealing with potential chemical migrants that regulators expect you to understand and control. What Are Extractables and Leachables? Extractables are chemical constituents that move out of a device or material under aggressive laboratory conditions, such as exaggerated temp

Medical device biocompatibility evaluation involves two distinct but complementary approaches: chemical characterization and biological testing. Understanding when each is required—and how they work together—is essential for efficient regulatory submissions and comprehensive safety evaluation. Many manufacturers struggle with determining the appropriate balance between these approaches. Over-reliance on biological testing can miss critical chemical safety concerns, while foc